May 3, 2019

End Duchenne Tour Recap: Portland, ME

PPMD had the opportunity to travel to Portland, ME on April 27 for our third End Duchenne Tour stop of 2019. We were joined by 14 local families, 11 of our industry partners, and 3…

Learn More

February 25, 2019

Santhera’s SYROS Study Shows Long-term Efficacy with Idebenone in Slowing Respiratory Function Loss

Santhera Pharmaceuticals announced positive results from the SYROS study demonstrating that long-term treatment with idebenone consistently reduced the rate of respiratory function loss in patients with Duchenne for up to 6 years in a real-world…

Learn More

February 19, 2019

End Duchenne Tour Recap: Las Vegas, NV

PPMD was thrilled to head to Las Vegas, NV for our first End Duchenne Tour stop of 2019 on February 2. More than 45 people came together to learn about the latest information and resources for Duchenne…

Learn More

December 17, 2018

End Duchenne Tour Recap: Cincinnati, OH

PPMD headed to Cincinnati, OH for our End Duchenne Tour stop on November 17, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families. PPMD…

Learn More

November 29, 2018

End Duchenne Tour Recap: Palo Alto, CA

PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families….

Learn More

May 18, 2018

Santhera Pharmaceuticals Launches Formal Expanded Access Program in the U.S.

PPMD is pleased to learn that Santhera Pharmaceuticals has launched a formal expanded access program in the U.S. for their investigational therapies, including idebenone. Learn more by visiting the Santhera website.

Learn More